دورية أكاديمية
أعرض في EDS

Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis.

التفاصيل البيبلوغرافية
العنوان: Checkpoint kinase 1 is essential for normal B cell development and lymphomagenesis.
المؤلفون: Schuler F; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Weiss JG; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Lindner SE; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Lohmüller M; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Herzog S; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Spiegl SF; Division of Molecular Pathophysiology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Menke P; Division of Molecular Pathophysiology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Geley S; Division of Molecular Pathophysiology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Labi V; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria., Villunger A; Division of Developmental Immunology, Biocenter, Medical University of Innsbruck, Innrain 80, A-6020, Innsbruck, Austria. andreas.villunger@i-med.ac.at.; Tyrolean Cancer Research Institute, Innrain 66, A-6020, Innsbruck, Austria. andreas.villunger@i-med.ac.at.
المصدر: Nature communications [Nat Commun] 2017 Nov 22; Vol. 8 (1), pp. 1697. Date of Electronic Publication: 2017 Nov 22.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [London] : Nature Pub. Group
مواضيع طبية MeSH: B-Lymphocytes/*enzymology , Checkpoint Kinase 1/*physiology , Lymphoma/*enzymology, Animals ; Apoptosis ; B-Lymphocytes/cytology ; Burkitt Lymphoma/drug therapy ; Burkitt Lymphoma/enzymology ; Burkitt Lymphoma/pathology ; Carcinogenesis/genetics ; Carcinogenesis/metabolism ; Cell Differentiation/genetics ; Cell Differentiation/physiology ; Cell Line, Tumor ; Cell Survival/genetics ; Cell Survival/physiology ; Checkpoint Kinase 1/antagonists & inhibitors ; Checkpoint Kinase 1/deficiency ; Checkpoint Kinase 1/genetics ; DNA Damage ; Genes, myc ; Haploinsufficiency ; Humans ; Lymphoma/etiology ; Lymphoma/genetics ; Lymphopoiesis/genetics ; Lymphopoiesis/physiology ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Models, Biological ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/enzymology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology
مستخلص: Checkpoint kinase 1 (CHK1) is critical for intrinsic cell cycle control and coordination of cell cycle progression in response to DNA damage. Despite its essential function, CHK1 has been identified as a target to kill cancer cells and studies using Chk1 haploinsufficient mice initially suggested a role as tumor suppressor. Here, we report on the key role of CHK1 in normal B-cell development, lymphomagenesis and cell survival. Chemical CHK1 inhibition induces BCL2-regulated apoptosis in primary as well as malignant B-cells and CHK1 expression levels control the timing of lymphomagenesis in mice. Moreover, total ablation of Chk1 in B-cells arrests their development at the pro-B cell stage, a block that, surprisingly, cannot be overcome by inhibition of mitochondrial apoptosis, as cell cycle arrest is initiated as an alternative fate to limit the spread of damaged DNA. Our findings define CHK1 as essential in B-cell development and potent target to treat blood cancer.
References: Nat Cell Biol. 2005 Feb;7(2):195-201. (PMID: 15665856)
Science. 2000 May 26;288(5470):1425-9. (PMID: 10827953)
Science. 1997 Sep 5;277(5331):1501-5. (PMID: 9278512)
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20752-7. (PMID: 19091954)
EMBO J. 2007 Jun 6;26(11):2719-31. (PMID: 17491592)
Oncogene. 2014 Jul 31;33(31):4089-96. (PMID: 24037525)
Cancer Res. 2001 Nov 1;61(21):7727-30. (PMID: 11691784)
Cancer Res. 2007 Jul 15;67(14 ):6574-81. (PMID: 17638866)
Sci Signal. 2016 Sep 13;9(445):ra90. (PMID: 27625304)
Oncogene. 2009 Mar 19;28(11):1443-53. (PMID: 19169280)
Cancer Cell. 2004 Jul;6(1):45-59. (PMID: 15261141)
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14943-8. (PMID: 10611317)
Cell. 2012 Mar 30;149(1):22-35. (PMID: 22464321)
EMBO J. 1997 Feb 3;16(3):545-54. (PMID: 9034337)
Cell. 2015 Aug 27;162(5):944-7. (PMID: 26317463)
Oncotarget. 2015 Mar 30;6(9):6553-69. (PMID: 25544753)
Oncogene. 2010 Jul 15;29(28):4007-17. (PMID: 20473325)
Genes Dev. 2000 Jun 15;14 (12 ):1448-59. (PMID: 10859164)
Clin Cancer Res. 2011 Nov 15;17 (22):7067-79. (PMID: 21933891)
J Biol Chem. 2009 Dec 4;284(49):34223-30. (PMID: 19837665)
Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13789-94. (PMID: 16940357)
Dev Cell. 2007 Feb;12 (2):247-60. (PMID: 17276342)
Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5159-64. (PMID: 19289837)
Oncogene. 2006 Jan 19;25(3):338-48. (PMID: 16158051)
Nature. 1985 Dec 12-18;318(6046):533-8. (PMID: 3906410)
Oncogene. 2012 Mar 15;31(11):1366-75. (PMID: 21804609)
J Clin Invest. 2012 Jun;122(6):2165-75. (PMID: 22585575)
Mol Oncol. 2011 Aug;5(4):368-73. (PMID: 21820372)
Nat Struct Mol Biol. 2011 Nov 27;18(12 ):1331-1335. (PMID: 22120667)
Proc Natl Acad Sci U S A. 2006 Aug 8;103(32):11964-9. (PMID: 16873548)
Oncogene. 2012 Mar 29;31(13):1661-72. (PMID: 21841818)
PLoS One. 2010 Jan 05;5(1):e8581. (PMID: 20052416)
Leukemia. 2005 Jan;19(1):112-7. (PMID: 15526025)
Proc Natl Acad Sci U S A. 2007 Mar 6;104(10 ):3805-10. (PMID: 17360434)
Genome Res. 2002 Jan;12(1):98-111. (PMID: 11779835)
Cell Cycle. 2003 Nov-Dec;2(6):604-9. (PMID: 14504477)
Genes Dev. 2017 Jan 1;31(1):34-45. (PMID: 28130345)
Int J Cancer. 2014 Mar 1;134(5):1013-23. (PMID: 23613359)
EMBO J. 2010 Oct 20;29(20):3558-70. (PMID: 20834228)
Cell Rep. 2016 Dec 20;17 (12 ):3407-3416. (PMID: 28009306)
Mol Cell Biol. 2006 Apr;26(8):3319-26. (PMID: 16581803)
Science. 1997 Sep 5;277(5331):1497-501. (PMID: 9278511)
Mol Cell. 2006 Aug 4;23 (3):319-29. (PMID: 16885022)
Nat Cell Biol. 2006 Jan;8(1):37-45. (PMID: 16327781)
Cell. 2015 Feb 26;160(5):977-89. (PMID: 25723171)
Fam Cancer. 2010 Dec;9(4):537-40. (PMID: 20567916)
J Exp Med. 2012 Mar 12;209(3):455-61. (PMID: 22370720)
Genes Dev. 2010 Aug 1;24(15):1602-7. (PMID: 20679395)
Mol Cell. 2006 Aug 4;23 (3):307-18. (PMID: 16885021)
EMBO Rep. 2017 Sep;18(9):1604-1617. (PMID: 28705801)
Genes Dev. 2000 Jun 15;14 (12 ):1439-47. (PMID: 10859163)
معلومات مُعتمدة: I 3271 Austria FWF_ Austrian Science Fund FWF
المشرفين على المادة: EC 2.7.11.1 (CHEK1 protein, human)
EC 2.7.11.1 (Checkpoint Kinase 1)
EC 2.7.11.1 (Chek1 protein, mouse)
تواريخ الأحداث: Date Created: 20171124 Date Completed: 20181001 Latest Revision: 20220408
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC5700047
DOI: 10.1038/s41467-017-01850-4
PMID: 29167438
قاعدة البيانات: MEDLINE
الوصف
تدمد:2041-1723
DOI:10.1038/s41467-017-01850-4